Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Real-World Utilization of Molecular Residual Disease Testing in Cancer Care

ONS 2026

The 51st Annual Oncology Nursing Society 

San Antonio, TX, May 13-17 , 2026

Poster presentation: Real-World Utilization of Molecular Residual Disease Testing in Cancer Care

Authors: Kelly J Brassil KJ, Holland E, Li Y, Slavin TJ, Stockl KM, Morin P

Medical Specialty: Oncology

Related content

Test FAQ
Haystack MRD Testing
Audio Podcast
Enhancing Cancer Treatment Decisions With Ultrasensitive MRD Testing
Test FAQ
Myeloma Measurable Residual Disease (MRD) Detection, Flow Cytometry
Publication
Advanced Minimal Residual Disease Detection Using a Novel Circulating Tumor DNA Assay: A Report of Two Cases
Publication
Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans
Publication
NGS defined measurable residual disease MRD after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
FAQ
LiquidSEQ

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.